Claims for Patent: 9,757,514

Summary for Patent: 9,757,514

Title:	Device, system and methods for the oral delivery of therapeutic compounds
Abstract:	Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade within the wall to release the drug to produce a therapeutic effect. The preparation can be coupled to a delivery mechanism having one or more balloons or other expandable devices which are expandable responsive to a condition in the small intestine or other GI lumen to advance the preparation out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.
Inventor(s):	Imran; Mir A. (Los Altos Hills, CA), Herrmann; Peter (San Jose, CA), Syed; Baber (Palo Alto, CA), Williams; Timothy H. (Campbell, CA), Ong; Chang Jin (Fremont, CA), Method; Greg (San Jose, CA)
Assignee:	Rani Therapeutics, LLC (San Jose, CA)
Application Number:	14/244,673
Patent Claims:	1. A swallowable device for delivering an antibody preparation into an intestinal wall of a patient's intestinal tract, the swallowable device comprising: a swallowable capsule sized to pass through the intestinal tract, the capsule having a capsule wall, a least a portion of which degrades upon exposure to a selected pH in an intestine while protecting the capsule wall from degradation in a stomach of the patient; at least one expandable member assembly disposed within the capsule comprising a first compartment in at least a partially non-expanded state and a second compartment in at least a partially non-expanded state, the first and second compartments being fluidically separated by a degradable valve which degrades upon exposure to fluid in the intestinal tract; a liquid contained in one of the compartments; a reactant contained in the other compartment, wherein when the valve degrades, the liquid and the reactant mix to produce a gas which expands at least the second compartment; a delivery mechanism coupled to the second compartment, the delivery mechanism comprising at least one piston-cylinder assembly; and at least one tissue penetrating member comprising: a. a proximal portion detachably coupled to the delivery mechanism; and b. a tissue penetrating distal portion; c. and an antibody preparation for delivery into the intestinal wall, the antibody preparation comprising particles of an antibody, the at least one tissue penetrating member configured to be retained in the intestinal wall; and wherein upon expansion of the second compartment, the at least one tissue penetrating member is advanced into the intestinal wall by the delivery mechanism where it is retained in the intestinal wall so as to deliver the therapeutic agent into the intestine. 2. The device of claim 1, wherein the antibody is a HER2 antibody. 3. The device of claim 1, wherein the antibody is Adalimumab. 4. The device of claim 1, wherein the antibody is Infliximab. 5. The device of claim 1, wherein the antibody is Etanercept. 6. The device of claim 1, wherein the antibody particles are micronized.

Details for Patent 9,757,514

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998		2030-12-23
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998		2030-12-23
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999		2030-12-23
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004		2030-12-23